Long-Term GAD-alum Treatment Effect on Different T-Cell Subpopulations in Healthy Children Positive for Multiple Beta Cell Autoantibodies
Table 2
Cross-sectional analysis stratified by treatment (GAD-alum/placebo) evaluating whether GAD-alum treatment is associated with different T-cell subpopulations during study follow-up.
Phenotyped T-cell populations
1Visit
2Estimate
95% CI
value
T-cells CD3+
8
-0.41
-0.7, -0.12
0.008
10
-0.36
-0.66, -0.06
0.022
CD3 + CD4+
8
-0.24
-0.43, -0.06
0.014
10
-0.20
-0.39, 0
0.048
CD4+ CD45RA+ CD45RO-
8
-0.18
-0.33, -0.03
0.019
CD4+ CD45RA+ CD45RO+
8
-0.03
-0.06, 0
0.038
CD4 + CD45RA + CD62L+
8
-0.19
-0.34, -0.05
0.013
CD4 + CD45RA + CD62L-
8
-0.01
-0.02, 0
0.039
CD4 + CD62L+
8
-0.25
-0.46, -0.05
0.017
CD4 + CD62L-
8
-0.03
-0.05, -0.01
0.008
CD3 + CD8+
8
-0.15
-0.28, -0.02
0.023
10
-0.12
-0.22, -0.02
0.018
CD8+ CD45RA+ CD45RO-
8
-0.11
-0.22, -0.01
0.035
10
-0.11
-0.20, -0.01
0.028
CD8 + CD45RA + CD62L+
8
-0.11
-0.2, -0.02
0.020
10
-0.11
-0.18, -0.03
0.011
CD8 + CD62L+
10
-0.09
-0.16, -0.01
0.023
CD8 + CD62L-
8
-0.06
-0.12, -0.01
0.032
1Visits 8 and 10 equal 18, respectively, 24 months of follow-up after first treatment dose. 2Estimated difference between GAD-alum-treated children and placebo-treated children. 95% CI: 95% confidence interval.
